Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy.  The MRC experience in 715 patients under 44 years with donors available

AK Burnett; Keith Wheatley; R Stevens; AH Goldstone; I Hann; AG Prentice; Donald Milligan; B Gibson; D Webb

Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patients under 44 years with donors available

AK Burnett, Keith Wheatley, R Stevens, AH Goldstone, I Hann, AG Prentice, Donald Milligan, B Gibson, D Webb

Research output: Contribution to conference (unpublished) › Paper

Original language	English
Pages	74a Abs 269
Publication status	Published - 1 Jan 2002

Cite this

@conference{3227304f4fa54ef389dc364d3c6aa15a,

title = "Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patients under 44 years with donors available",

author = "AK Burnett and Keith Wheatley and R Stevens and AH Goldstone and I Hann and AG Prentice and Donald Milligan and B Gibson and D Webb",

year = "2002",

month = jan,

day = "1",

language = "English",

pages = "74a Abs 269",

}

TY - CONF

T1 - Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patients under 44 years with donors available

AU - Burnett, AK

AU - Wheatley, Keith

AU - Stevens, R

AU - Goldstone, AH

AU - Hann, I

AU - Prentice, AG

AU - Milligan, Donald

AU - Gibson, B

AU - Webb, D

PY - 2002/1/1

Y1 - 2002/1/1

M3 - Paper

SP - 74a Abs 269

ER -